Artificial intelligence (AI) is entering the mainstream. The term encompasses a wide variety of machines that can learn from ...

Frailty is common in rheumatic diseases and linked to worse outcomes. Early screening and targeted prevention can improve ...

Objective To examine the performance of the new 2022 American College of Rheumatology (ACR)/EULAR giant cell arteritis (GCA) classification criteria for diagnosis in routine clinical care. Methods ...

Objective Recently the Diagnostic and Classification Criteria in Vasculitis Study group developed and published new American College of Rheumatology/EULAR classification criteria for giant cell ...

Researchers have discovered in a new study that glucocorticoid-induced adrenal insufficiency (GIAI) was rare (1.9%) in patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA ... 5 of ...

Objectives Evidence of the association of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) with the full range ... date on which the patient fulfilled all the study inclusion criteria, or ...

The following is a summary of “Population-Based Performance of Inflammatory Markers in Giant Cell Arteritis,” published in the March ... GCA followed the 1990 American College of Rheumatology criteria ...

Vascular ultrasound for giant cell arteritis has been shown to be cost-effective and ... MY conceptualised the search criteria and wrote the initial draft. MY and CD reviewed abstracts. MY, AJM, and ...

a patient with vasculitis shall be said to have giant cell temporal arteritis if at least three of these five criteria are present. Giant cell arteritis (GCA) is a medical emergency. The concept ...

WASHINGTON -- Giant cell arteritis (GCA) can be successfully treated ... was about 35 mg/day in prednisone equivalents. Eligibility criteria included having received steroid doses of at least ...

UK Objective To develop and validate updated classification criteria for giant cell arteritis (GCA). Methods Patients with vasculitis or comparator diseases were recruited into an international cohort ...

Following success in several indications including ulcerative colitis, J&J’s blockbuster drug Tremfya failed to meet a mid-stage study’s primary endpoint in treating giant cell arteritis. Johnson & ...